Table 1.

Current PARP inhibitors approved or in late stage development.

Drug	Company	IC50/nM	Relative PARP Trapping Potency [9,11]	Predominant Toxicities
Olaparib	Astra Zeneca	6	1	GI toxicities, fatigue, anemia
Rucaparib	Clovis	21	1	GI toxicities, fatigue, anemia, liver dysfunction
Niraparib	Tesaro	60	~2	Myelosuppression, GI toxicities, fatigue
Veliparib	AbbVie	30	<0.2	Fatigue, alopecia, GI toxicities, myelosuppression
Talazoparib	Pfizer	4	~100	GI toxicities, fatigue, lymphopenia